Previous Close | 11.98 |
Open | 12.13 |
Bid | 11.92 x 100 |
Ask | 12.20 x 300 |
Day's Range | 12.07 - 13.11 |
52 Week Range | 0.66 - 14.30 |
Volume | |
Avg. Volume | 5,588,558 |
Market Cap | 360.277M |
Beta (5Y Monthly) | -0.93 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
Key Insights The considerable ownership by retail investors in Candel Therapeutics indicates that they collectively...
Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.